Search Results - Christopher L Bowlus

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Primary sclerosing cholangitis: A review and update by James H. Tabibian, Christopher L. Bowlus

    Published in Liver Research (2017-12-01)
    Get full text
    Article


  2. 2

    Analysis of the IDDM Candidate Gene Prss16 in NOD and NON Mice by Saijai Cheunsuk, Tom Hsu, M. Eric Gershwin, Christopher L. Bowlus

    Published in Clinical and Developmental Immunology (2002-01-01)
    Get full text
    Article


  3. 3

    Gene Expression by PBMC in Primary Sclerosing Cholangitis: Evidence for Dysregulation of Immune Mediated Genes by Christopher A. Aoki, Kevin Dawson, Thomas P. Kenny, M. Eric Gershwin, Christopher L. Bowlus

    Published in Clinical and Developmental Immunology (2006-01-01)
    Get full text
    Article


  4. 4

    Fecal deoxycholic acid associates with diet, intestinal microbes, and total bilirubin in primary sclerosing cholangitis by Connie Chan, Mateus Lemos, Peter Finnegan, William Gagnon, Richard Dean, Maryam Yazdanafar, Joseph Zepeda, Marie-Claude Vohl, Michael Trauner, Joshua R. Korzenik, Olivier Barbier, Maria L. Marco, Christopher L. Bowlus

    Published in JHEP Reports (2024-12-01)
    Get full text
    Article


  5. 5

    Per-oral cholangioscopy in patients with primary sclerosing cholangitis: a 12-month follow-up study by Rachid Mohamed, Sooraj Tejaswi, Lars Aabakken, Cyriel Y Ponsioen, Christopher L Bowlus, Douglas G Adler, Nauzer Forbes, Vemund Paulsen, Rogier P. Voermans, Shiro Urayama, Joyce Peetermans, Matthew J Rousseau, Bertus Eksteen

    Published in Endoscopy International Open (2024-02-01)
    Get full text
    Article


  6. 6

    Decreased CD57 expression of natural killer cells enhanced cytotoxicity in patients with primary sclerosing cholangitis by Bin Liu, Bin Liu, Guo-Xiang Yang, Ying Sun, Ying Sun, Takashi Tomiyama, Takashi Tomiyama, Weici Zhang, Patrick S. C. Leung, Xiao-Song He, Sandeep Dhaliwal, Pietro Invernizzi, M. Eric Gershwin, Christopher L. Bowlus

    Published in Frontiers in Immunology (2022-08-01)
    Get full text
    Article


  7. 7

    EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL by Alejandra M. Villamil, Ziad Younes, Christopher L. Bowlus, John M. Vierling, Adam Vasura, Andrea Galli, Mordechai Rabinovitz, Frederik Nevens, Susheela Carroll, Ke Yang, Daria B. Crittenden, Charles A. McWherter, Eric J. Lawitz

    Published in Annals of Hepatology (2025-09-01)
    Get full text
    Article


  8. 8

    Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis by Tagreed A. Mazi, Kamil Borkowski, Oliver Fiehn, Christopher L. Bowlus, Souvik Sarkar, Karen Matsukuma, Mohamed R. Ali, Dorothy A. Kieffer, Yu-Jui Y. Wan, Kimber L. Stanhope, Peter J. Havel, John W. Newman, Valentina Medici

    Published in Metabolites (2022-02-01)
    Get full text
    Article


  9. 9

    PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with p... by Michael Trauner, Chuhan Chung, Kate Sterling, Xiangyu Liu, Xiaomin Lu, Jun Xu, Clare Tempany-Afdhal, Zachary D. Goodman, Martti Färkkilä, Atsushi Tanaka, Palak Trivedi, Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Robert P. Myers

    Published in BMC Gastroenterology (2023-03-01)
    Get full text
    Article


  10. 10

    Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy by Yu Chen, Haoyu Wen, You Li, Weituo Zhang, Tianyu Mao, Chenyi Jiang, Huayang Zhang, Yujie Zhou, Xiting Pu, Bo Li, Jun Zhang, Li Yan, Min Lian, Li Sheng, Canjie Guo, Qixia Wang, Qi Miao, Jing Hua, Hai Li, Ruqi Tang, Christopher L. Bowlus, M. Eric Gershwin, Zhengrui You, Xiao Xiao, Xiong Ma

    Published in JHEP Reports (2025-09-01)
    Get full text
    Article


  11. 11

    OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY by Palak J. Trivedi, Cynthia Levy, Kris V. Kowdley, Stuart C. Gordon, Christopher L. Bowlus, Maria Carlota Londoño Hurtado, Gideon M. Hirschfield, Aliya F. Gulamhusien, Eric J. Lawitz, Alejandra Villamil, Alma Ladron de Guevara Cetina, Marlyn J. Mayo, Ziad H. Younes, Oren Shibolet, Kidist K. Yimam, Daniel S. Pratt, Jeong Heo, Ulrike Morgera, Pietro Andreone, Andreas E. Kremer, Christophe Corpechot, Aparna Goel, Adam Peyton, Hany Elbeshbeshy, Daria B. Crittenden, Carrie Heusner, Sarah Proehl, Shuqiong Zhou, Charles A. McWherter

    Published in Annals of Hepatology (2024-12-01)
    Get full text
    Article


Search Tools: